Faxed prescriptions will only be accepted from a prescriber. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to Senderra.

| | | Juvenile Idiopathic Arthritis (JIA) Enrollment Form A-H | | Prescriber: | | | | | | | NPI: | | | |
|--|--|--|---|------------------------|-------------------------|-----------------|--------------|-------------|----------|-----------|-------------|--------------|--------------|--|
| | | | | Supervising Physician: | | | | | | NPI: | | | | |
| SENDERRA Specialty Pharmacy 1301 E. Arapaho Rd., Ste. 101 | | Physician Offices Call: 855-460-7928 Fax: 888-777-5645 | | Address: | | | | | | Tax ID: | | | | |
| | | | | Phone: Fax: | | | | | | | | | | |
| Richardson, TX 75081 This prescription form is to be sent & received via fax | | | | Contact: | | | | | | | | | | |
| | | | | PATIENT INFORMATION | | | | | | | | | | |
| Name: | | | = 🛛 Trans | M Trans F Other | | | | 1 1 | | | SS#: - | - | | |
| Street: | | · | City: | State: | | | | | ZIP: | | | | | |
| Phone: | | Alt. Phone: | | English Spanish Other: | | | | | W | Wt.: Ht.: | | | | |
| PRESCRIPTION □New □ Refill Ship by:// SHIP TO: □ Patient's Home □ Doctor's Office □ Other: | | | | | | | | | | | | | | |
| Drug | efill Ship by: | // | | SHIP | | t's H rectio | | octor's C | Office L | Oth | ner: | Quantity | _ Refills | |
| Actemra® | | INTRAVE | NOUS (IV): | | | recin | 0115 | | | | | Quantity | Reillis | |
| | D _{Vial} | | □ PJIA – Infuse 10 mg/kg every 4 weeks via IV (< 30 kg) | | | | | | | | | | | |
| | | | □ PJIA – Infuse 8 mg/kg every 4 weeks via IV (≥ 30 kg) ***WEIGHT REQUIRED*** | | | | | | | | | | | |
| | | | □ SJIA – Infuse 12 mg/kg every 2 weeks via IV (< 30 kg) | | | | | | | | | | | |
| | | | | | y 2 weeks via I∖ | ⁄ (≥ 3 | 0 kg) | | | | | | | |
| | | | | | co overv 3 wee | ke le | 30 ka) | | | | | 1 | | |
| | Pre-filled Syringe ACTPen[®] | | □ PJIA – Inject 162 mg SQ once every 3 weeks (< 30 kg) □ PJIA – Inject 162 mg SQ once every 2 weeks (≥ 30 kg) ***WEIGHT REQUIRED** | | | | | | | | | 2 | | |
| | | | □ SJIA – Inject 162 mg SQ once every 2 weeks (< 30 kg) | | | | | | | | | | | |
| | | | | | nce weekly (≥ 3(| | | | | | - | 4 | | |
| Cosentyx® | Pre-filled Syringe | | : Inject 75 i | mg SQ at | t week 0, 1, 2, 3 | , and | l 4 (≥ 15 kg | j to < 50 k | g) | ***\ | VEIGHT | 5 | | |
| | | | MAINTENANCE: Inject 75 mg SQ every 4 weeks | | | | | | | | | | | |
| | Sensoready Pen Pre-filled Syringe | | □ INITIAL: Inject 150 mg SQ at week 0, 1, 2, 3, and 4 (≥ 50 kg) □ MAINTENANCE: Inject 150 mg SQ every 4 weeks | | | | | | | | | 5 | | |
| Enbrel® | □ SureClick [®] Pen □ Mini [®] with AutoToucl | — | | | | | | | | | JIRED*** | x 25 | | |
| | Pre-filled Syringe | | | | | | | | | | - | mg/0.5 mL | | |
| | □ 25 mg □ 50 mg □ 25 mg Vial | g 🛛 Inject 50 | □ Inject 50 mg SQ every week (>63 kg) | | | | | | | | | 4 | | |
| Humira [®] Citrate Free | □ Pre-filled Syringe □ Pen | very other week (10 kg to <15 kg) very other week (15 kg to <30 kg) ****WEIGHT RE | | | | | EQU | IIRED*** | | | | | | |
| □ Inject 40 mg SQ every other week (≥ 30 kg) | | | | | | | | | | | | | | |
| MEDICAL INFORMATION ****PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY*** | | | | | | | | | | | | | | |
| PREVIOUS THERA | | | d & Failed (Duration): Not Tolerated: | | | | | | | ntrai | indication: | | | |
| Methotrexate | | |) | | | | | | | | | | | |
| Enbrel | | (|) | | | | | | | | | | | |
| Humira | | |) | | | | | | | | | | | |
| □ | | | | | | | | | | | | | | |
| Date of Diagnosis: | <u> </u> | | | Allerg | gies: | | | | | | | | | |
| M08.00 Unspecified juvenile idiopathic arthritis of unspecified site M08.09 Unspecified juvenile rheumatoid arthritis, multiple sites (pcJIA) | | | | | | | | | | | | | | |
| M08.80 Other juvenile arthritis, unspecified site (Enthesitis-related arthritis) | | | | | | | | | | | | | | |
| □ _{Other:} | | | | | | | | | | | | | | |
| Active TB is ruled out: DYes DNo Date: / / Hep B ruled out/treated: DYes DNo Date: / / / | | | | | | | | | | | | | | |
| Additional Clinical Information: | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| INJECTION TRAINING | | | | | | | | | | | | | | |
| Patient has received pen and injection training Physician's office to provide injection training Senderra to coordinate injection training | | | | | | | | | | | | | | |
| The second point and injection daming PRESCRIBER SIGNATURE <u>To Prescriber:</u> By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance | | | | | | | | | | | | | | |
| companies, and co-pay Prescriber: | assistance foundations. | , <u>,</u> are di | | | , | | | | Date | | | , | | |
| | | | | CONER | ENTIALITY NOT | | | | | | / | / | | |
| | s intended to be delivered only not disseminate, distribute, or c | | | ntains mater | rial that is confident | ial, pro | | | | | | | named | |
| | , alou loado, or c | , , | , | | | | | | | | | | | |